Endoglin in HIV-associated preeclamptic placentae

REFERENCES

• Agarwal I, Karumanchi SA. Preeclampsia and the anti-angiogenic state. Pregnancy Hypertens 2011;1:17–21
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Eng J Med 2006;355:992–1005
   PubMed Web of Science ®Google Scholar
• Gregory AL, Xua G, Sotov V, Letarte M. Review: the enigmatic role of endoglin in the placenta. Placenta 2014;35(Supplement):593–9
   Google Scholar
• Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011;123:2856–69
   PubMed Web of Science ®Google Scholar
• Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011;31:33–46
   PubMed Web of Science ®Google Scholar
• Govender N, Moodley J, Gathiram P, Naicker T. Soluble fms-like tyrosine kinase-1 in HIV infected pre-eclamptic South African Black women. Placenta 2014;35:618–24
   PubMed Web of Science ®Google Scholar
• Naicker T, Dorsamy E, Ramsuran D, et al. The role of apoptosis on trophoblast cell invasion in the placental bed of normotenisve and preeclamptic pregnancies. Hypertens Pregnancy 2013;32:245–56
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim SY, Park SY, et al. Soluble endoglin and transforming growth factor-β1 in women who subsequently developed preeclampsia. Prenatal Diagnosis 2009;29:471–6
   PubMed Web of Science ®Google Scholar
• Lopez-Novoa JM. Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia. Nephrol Dial Transplant 2007;22:712–4
   PubMed Web of Science ®Google Scholar
• Maynard SE, Venkatesha S, Thandhani R, Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005;57:1R–7R
   PubMed Web of Science ®Google Scholar
• Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 2006;21:3052–4
   PubMed Web of Science ®Google Scholar
• Salahuddin S, Lee Y, Vadnais M, et al. Diagnostic utility of soluble fmslike tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007;197:e1–28.e6
   Google Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–9
   PubMed Web of Science ®Google Scholar
• Govender N, Naicker T, Rajakumar R, Moodley J. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia. Eur J Obstet Gynecol Reprod Biol 2013;170:100–5
   PubMed Web of Science ®Google Scholar
• Govender N, Naicker T, Moodley J. Maternal imbalance between pro-angiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia. Cardiovasc J Afr 2013;24:174–9
   PubMed Web of Science ®Google Scholar
• Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretro viral therapy, and immune reconstitution. Lancet 2002;360:1152–54
   PubMed Web of Science ®Google Scholar
• Stratton P, Tuomala R, Abboud R. Obstetric and newborn outcomes in a cohort of HIV infected pregnant women: a report of the women and infants transmission study. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:179–86
   PubMedGoogle Scholar
• Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006;20:59–66
   PubMed Web of Science ®Google Scholar
• Reynolds ES. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol 1963;17:208–12
   PubMed Web of Science ®Google Scholar
• Umareddy I, Pluquet O, Wang Q, et al. Dengue virus serotype infection specifies the activation of the unfolded protein response. Virol J 2007;6:91
   Google Scholar
• Red-Horse K, Zhou Y, Genbacev O, et al. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest 2004;114:744–54
   PubMed Web of Science ®Google Scholar
• Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008;93:260–6
   PubMed Web of Science ®Google Scholar
• Yinon Y, Nevo O, Xu J, et al. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels – hypoxic regulation via transforming growth factor beta 3. Am J Pathol 2008;172:77e85
   Google Scholar
• Guller S, Tang Z, Ma YY, et al. Protein composition of microparticles shed from human placenta during placental perfusion: potential role in angiogenesis and fibrinolysis in preeclampsia. Placenta 2011;32:63–9
   PubMed Web of Science ®Google Scholar
• Tannetta DS, Dragovic RA, Gardiner C, et al. Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Flt-1 and endoglin. PLoS One 2013;8:e56754
   PubMed Web of Science ®Google Scholar
• Rajakumar A, Cerdeira AS, Rana S, et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble Fms-like tyrosine kinase 1 in preeclampsia. Hypertension 2012;59:256–64
   PubMed Web of Science ®Google Scholar
• Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 1998;105:632–40
   PubMedGoogle Scholar
• Maynard SE, Moore Simas TA, Bur L, et al. Soluble endoglin for the prediction of preeclampsia in a high risk cohort. Hypertens Pregnancy 2010;29:330–41
   PubMed Web of Science ®Google Scholar
• Levine RJ, Karamanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005;48:372–86
   PubMed Web of Science ®Google Scholar
• Vatten LJ, Eskild A, Nilsen TIL, et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynaecol 2007;196:239.e1–.e6
   PubMed Web of Science ®Google Scholar
• Eskild A, Vatten LJ. Do pregnancies with pre-eclampsia have smaller placentas? A population study of 317 688 pregnancies with and without growth restriction in the offspring. Br J Obstet Gynaecol 2010;117:1521–6
   Google Scholar
• Stepan H, Kramer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007;92:2831–4
   PubMed Web of Science ®Google Scholar
• Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010;122:478–87
   PubMed Web of Science ®Google Scholar
• Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 2007;92:2672–9
   PubMed Web of Science ®Google Scholar
• von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143–8
   PubMed Web of Science ®Google Scholar